LB Pharmaceuticals to present at investor conferences on March 11 and March 17, highlighting its neuropsychiatric therapies.
Quiver AI Summary
LB Pharmaceuticals Inc, a late-stage biopharmaceutical company focused on developing innovative therapies for neuropsychiatric conditions such as schizophrenia and bipolar depression, announced its participation in two upcoming investor conferences. Management will present at the Leerink 2026 Global Healthcare Conference on March 11, 2026, and the Stifel 2026 Virtual CNS Forum on March 17, 2026. Both presentations will be available via live webcast on the company's website, with replays archived for later viewing. The company aims to advance its lead product candidate, LB-102, which could potentially be the first approved benzamide antipsychotic in the U.S., offering clinicians a viable alternative in psychiatric treatment.
Potential Positives
- LB Pharmaceuticals will present at prominent investor conferences, enhancing visibility and engagement with the investment community.
- The Company's lead product candidate, LB-102, has the potential to be a groundbreaking treatment in neuropsychiatry, possibly becoming a mainstay in psychiatric practice.
- The webcast availability of the presentations may attract a broader audience of investors and stakeholders, fostering transparency and interest in the Company's developments.
Potential Negatives
- Management's participation in multiple investor conferences may imply a need for increased investor reassurance due to potential instability or uncertainty surrounding the company's pipeline and market position.
FAQ
What is LB Pharmaceuticals' main focus?
LB Pharmaceuticals specializes in developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases.
When will LB Pharmaceuticals present at investor conferences?
LB Pharmaceuticals will present at the Leerink 2026 Global Healthcare Conference on March 11 and the Stifel 2026 Virtual CNS Forum on March 17.
Where can I watch the LB Pharmaceuticals presentations?
A live webcast of the presentations will be available on the Company's website under the "Investors" section.
What is LB-102?
LB-102 is LB Pharmaceuticals' lead product candidate, aiming to be a first benzamide antipsychotic approved for neuropsychiatric disorders in the U.S.
Who can I contact for media inquiries about LB Pharmaceuticals?
For media inquiries, contact Ellen Rose at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LBRX Insider Trading Activity
$LBRX insiders have traded $LBRX stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LBRX stock by insiders over the last 6 months:
- TRACK BIOTECHNOLOGY MASTER FUND, LTD. DEEP has made 2 purchases buying 2,666,666 shares for an estimated $39,999,990 and 0 sales.
- RAN NUSSBAUM purchased 1,000,000 shares for an estimated $15,000,000
- MANAGEMENT 4 G.P. (2015) LTD. PONTIFAX purchased 1,000,000 shares for an estimated $15,000,000
- VENTURES GP III, L.L.C. VIDA has made 2 purchases buying 333,333 shares for an estimated $4,999,995 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LBRX Hedge Fund Activity
We have seen 47 institutional investors add shares of $LBRX stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 1,263,934 shares (+129.6%) to their portfolio in Q4 2025, for an estimated $28,135,170
- VANGUARD GROUP INC added 1,112,978 shares (+inf%) to their portfolio in Q4 2025, for an estimated $24,774,890
- JPMORGAN CHASE & CO added 578,879 shares (+56.1%) to their portfolio in Q4 2025, for an estimated $12,885,846
- MILLENNIUM MANAGEMENT LLC removed 538,169 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $11,979,641
- RA CAPITAL MANAGEMENT, L.P. added 431,646 shares (+24.3%) to their portfolio in Q4 2025, for an estimated $9,608,439
- GEODE CAPITAL MANAGEMENT, LLC added 427,863 shares (+3148.1%) to their portfolio in Q4 2025, for an estimated $9,524,230
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 390,000 shares (-97.5%) from their portfolio in Q4 2025, for an estimated $8,681,400
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LBRX Analyst Ratings
Wall Street analysts have issued reports on $LBRX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 12/11/2025
- Piper Sandler issued a "Overweight" rating on 10/06/2025
- Leerink Partners issued a "Outperform" rating on 10/06/2025
To track analyst ratings and price targets for $LBRX, check out Quiver Quantitative's $LBRX forecast page.
$LBRX Price Targets
Multiple analysts have issued price targets for $LBRX recently. We have seen 3 analysts offer price targets for $LBRX in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Paul Matteis from Stifel set a target price of $35.0 on 12/11/2025
- Yasmeen Rahimi from Piper Sandler set a target price of $78.0 on 10/06/2025
- Marc Goodman from Leerink Partners set a target price of $34.0 on 10/06/2025
Full Release
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced that management will present and participate in the following upcoming investor conferences:
Leerink 2026 Global Healthcare Conference
Date:
Wednesday, March 11, 2026
Time:
1:40 p.m. ET
Stifel 2026 Virtual CNS Forum
Date:
Tuesday, March 17, 2026
Time:
2:30 p.m. ET
A live webcast of the presentations will be available on the “Investors” section under the “ Events ” section of the Company’s website at https://lbpharma.us/ where a replay of the webcasts will be archived.
About LB Pharmaceuticals
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Media and Investor Contact
Ellen Rose
[email protected]
